NCT01557933

Brief Summary

The primary purpose of this study is to use magnetic resonance spectroscopy (MRS) to measure the levels of several brain chemicals including, but not limited to, glutamate, glutamine, and N-acetylaspartate, before and after treatment with ECT. In addition to MRS, the investigators will use several other MRI techniques including structural MRI, resting state functional MRI (fMRI), and diffusion tensor imaging (DTI) to measure how the structure and function of the brain changes with ECT. The investigators hypothesize that the Gln/Glu ratio is increased in the anterior cingulate cortex (ACC), but not the parieto-occipital cortex (POC), following the first ECT treatment.

Trial Health

15
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Apr 2011

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2011

Completed
11 months until next milestone

First Submitted

Initial submission to the registry

March 9, 2012

Completed
11 days until next milestone

First Posted

Study publicly available on registry

March 20, 2012

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2012

Completed
Last Updated

November 29, 2012

Status Verified

November 1, 2012

Enrollment Period

1.3 years

First QC Date

March 9, 2012

Last Update Submit

November 28, 2012

Conditions

Keywords

ECTBipolar Disorder

Outcome Measures

Primary Outcomes (1)

  • Gln/Glu ratio following the first ECT treatment

    The Gln/Glu ratio is examined in the anterior cingulate cortex (ACC) and the parieto-occipital cortex (POC) following the first ECT treatment.

    Participants will undergo an MR scan within 24 hours of their first ECT treatment

Secondary Outcomes (1)

  • The Gln/Glu ratio following the sixth ECT treatment.

    Participants will undergo an MR scan within 24 hours of their sixth ECT treatment, which is approximately two weeks after their first ECT treatment

Study Arms (1)

ECT

All study subjects have consented to receive ECT.

Other: No interventions will be used

Interventions

No interventions will be used

ECT

Eligibility Criteria

Age18 Years - 55 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Twelve study participants between the ages of 18-55 with will be recruited from inpatient units at McLean Hospital.

You may qualify if:

  • Male or female age 18-55
  • Meets DSM-IV criteria for Bipolar Disorder Type I, II, or NOS with current episode depressed
  • Has been scheduled to be evaluated by an ECT consultant from the McLean Hospital ECT service
  • Current score of greater than or equal to 24 on the Montgomery-Asberg Depression Rating Scale (MADRS)

You may not qualify if:

  • Unwillingness or inability to provide informed consent
  • Lifetime history of schizophrenia
  • DSM-IV diagnosis of alcohol or substance dependence, with the exception of nicotine dependence, within three months prior to screening
  • Positive urine toxicology screen at screening (NOTE: Participants with a positive urine toxicology screen who are prescribed benzodiazepine, stimulant, or opiate medications by their physician will be permitted to enroll in the study as long as they do not meet abuse or dependence criteria for these substances)
  • Female participants with a positive urine pregnancy test at screening
  • Pregnancy. Females of childbearing potential must be using an effective contraceptive method (e.g., abstinence, prescription oral contraceptives, contraceptive injections, MRI-safe intrauterine device, double-barrier method, male partner sterilization)
  • Any contraindications to having an MRI scan, including cardiac pacemakers, metal vascular clips or stents, artificial heart valves, certain kinds of prostheses, brain stimulator devices, implanted drug pumps, ear implants, eye implants or known metal fragments in eyes, exposure to shrapnel or metal filings (wounded in military combat, sheetmetal workers, welders, and others), transdermal drug delivery systems, and certain tattoos with metallic ink. NOTE: Participants will be screened for these conditions at screening, and will be required to fill out a standard MRI screening form at the Brain Imaging Center, which will be reviewed by an MRI technician prior to each MRI scan
  • Scheduled to receive first ECT treatment on a Friday

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Bipolar Disorder

Condition Hierarchy (Ancestors)

Bipolar and Related DisordersMood DisordersMental Disorders

Study Officials

  • Brian P Brennan, M.D.

    Mclean Hospital

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Director for Translational Neuroscience Research

Study Record Dates

First Submitted

March 9, 2012

First Posted

March 20, 2012

Study Start

April 1, 2011

Primary Completion

July 1, 2012

Study Completion

July 1, 2012

Last Updated

November 29, 2012

Record last verified: 2012-11